FOLFOX4化疗方案联合免疫治疗在中晚期肝癌中的应用价值(附2例报告)

目的:探讨FOLFOX4化疗方案联合全身免疫治疗在中晚期肝细胞癌中的应用价值及疗效。方法:回顾性分析2例在空军军医大学唐都医院就诊的中晚期肝癌患者资料,给予FOLFOX4全身化疗联合胸腺法新的免疫治疗后患者病情缓解,疾病完全控制。分析FOLFOX4化疗方案在中晚期肝癌中的应用价值,及联合应用时机选择。结果:2例中晚期患者中,其中1例患者合并有双肺转移瘤,全身化疗后7个周期肺转移瘤消失,肿瘤标志物降至正常。另1例患者肝癌破裂根治术后,患者腹腔转移瘤切除术后,给予全身联合治疗,患者2年内病情稳定,肿瘤标志物正常。结论:FOLFOX4化疗方案在中晚期肝癌患者中的效果是肯定的,联合胸腺法新的全身辅助免疫治疗有助于增强全身化疗的疗效,改善患者的总体生存预后。

The value of FOLFOX4 combined with immunotherapy in advanced hepatocellular carcinoma:2 cases of medical records

Objective:To explore the value and efficacy of FOLFOX4 combined with systemic immunotherapy in advanced hepatocellular carcinoma.Methods:To retrospectively analyze patients data with advanced hepatocellular carcinoma in our hospital.Patients were given FOLFOX4 systemic chemotherapy combined immunotherapy in remission,patients disease was completely controlled.Results:Among the two advanced patients,one patient had a double-lung metastasis tumor,the lung metastasis disappeared in 7 cycles after FOLFOX4 regimen systemic chemotherapy,the tumor markers were reduced to normal.The other patient had a metastatic tumor of the abdominal cavity after radical resection of liver cancer.After resection,systemic combination therapy was given,patient's condition was stable within 2 years and the tumor markers were normal.Conclusion:The effect of FOLFOX4 regimen in patients with advanced hepatocellular carcinoma is positive.Combined with Tα1 immunotherapy can enhance the efficacy of systemic chemotherapy and improve the overall survival prognosis of patients.